Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1978 1
1979 1
1980 2
1981 1
1982 2
1985 1
1988 1
1989 1
1991 1
1993 1
1996 1
2000 1
2001 2
2002 3
2003 9
2004 9
2005 14
2006 11
2007 9
2008 7
2009 2
2010 9
2011 3
2012 5
2013 7
2014 7
2015 7
2016 8
2017 8
2018 6
2019 6
2020 7
2021 1
2022 3
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, Naldi L, Lynde C, De Bruin-Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC, Conrad C, Fleischer A, Laquer VT, Misery L, Serra-Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C, Ständer S; OLYMPIA 2 Investigators. Kwatra SG, et al. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. N Engl J Med. 2023. PMID: 37888917 Clinical Trial.
Tremfya™ (Guselkumab).
Abramovits W, Wiqas A, Vincent KD, Versteeg SG, Gupta AK. Abramovits W, et al. Skinmed. 2019 Mar 19;17(1):36-38. eCollection 2019. Skinmed. 2019. PMID: 30888946 No abstract available.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Atopic dermatitis.
Abramovits W. Abramovits W. J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S86-93. doi: 10.1016/j.jaad.2005.04.034. J Am Acad Dermatol. 2005. PMID: 15968268 Review.
Cimzia™ (Certolizumab Pegol).
Abramovits W, Wiqas A, Vincent KD, Versteeg SG, Gupta AK. Abramovits W, et al. Skinmed. 2018 Dec 21;16(6):400-402. eCollection 2018. Skinmed. 2018. PMID: 30575508 No abstract available.
COSENTYX (Secukinumab).
Gupta AK, Foley KA, Abramovits W. Gupta AK, et al. Among authors: abramovits w. Skinmed. 2015 Aug 1;13(4):303-6. eCollection 2015 Jul-Aug. Skinmed. 2015. PMID: 26861430 No abstract available.
AMELUZ™ (BF-200 ALA).
Gupta AK, Versteeg SG, Abramovits W. Gupta AK, et al. Among authors: abramovits w. Skinmed. 2017 Apr 1;15(2):133-135. eCollection 2017. Skinmed. 2017. PMID: 28528609 No abstract available.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Light-emitting diode-based therapy.
Abramovits W, Arrazola P, Gupta AK. Abramovits W, et al. Skinmed. 2005 Jan-Feb;4(1):38-41. doi: 10.1111/j.1540-9740.2005.03959.x. Skinmed. 2005. PMID: 15654163 Review. No abstract available.
Sulfur/sodium sulfacetamide preparations.
Abramovits W, Kennedy AJ. Abramovits W, et al. Skinmed. 2004 Mar-Apr;3(2):95-101. doi: 10.1111/j.1540-9740.2004.03413.x. Skinmed. 2004. PMID: 15010636 Review. No abstract available.
168 results